Article
Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
The oncologist - 6 Apr 2023
Zhou Yongjian, Zeng Chunling, Sun Xiaofeng, Zhang Jun, Qu Hongyan, Zhang Xinhua, Zhou Ye, Liu Zimin, Wu Xiaojun, Wu Xin, Jiao Xuelong, Shen Lin, Zhou Yanbing, Wang Yuexiang, Li Jian
Abstract excerpt
BACKGROUND: Anlotinib is a multi-target tyrosine kinase inhibitor that can effectively inhibit tumor cell proliferation after receptor kinase activation caused by KIT gene mutation. METHODS: We tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations and evaluated the efficacy of anlotinib for patients with metastatic GIST after imatinib failure in a multicenter, single-arm,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.